June 12 – 17, 2022
Rabies is a viral fatal disease transmitted to humans from bites of infected animals. Due to nearly 95 % of human infections are related with dog bites, the WHO, OIE and FAO agreed in the implementation of a worldwide plan for the elimination of dog-mediated human rabies death by 2030. On the other hand, in some Latin-American countries paralytic bovine rabies transmitted by vampire bats causes economic losses to the farming industry. In this context, it is important to develop an economic vaccine that could be produced in a short period of time.
Our research group have been working in the development and validation of a recombinant rabies vaccine based on virus‑like particles (RV-VLPs), expressing the rabies glycoprotein in HEK293 cells1. Performing a rational design, we carried out the expression vectors construction, stable cell line development and the full biochemical and morphological characterization of the expressed RV-VLPs. On the other hand, the immune response triggered by these VLPs in mice was analysed, demonstrating that this new antigen is able to induce a potent humoral immune response with high titers of neutralizing antibodies. Furthermore, protection against rabies virus challenge was confirmed in NIH potency test assays, demonstrating that RV-VLPs are an excellent new generation and virus-free vaccine candidate.
Please click Download on the upper right corner to see the full abstract.
Claudio Prieto, Diego Fontana, Federico Marsili, Ricardo Kratje, and Marina Etcheverrigaray, "RHABDO-LIKE RECOMBINANTE (VLPs), a novel veterinary rabies vaccine: Safety and efficacy trials in pets and cattle" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/106